Review on SLC19A3, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
Transcription
5 transcript variants for SLC19A3 are described from the NCBI Homo sapiens Annotation Release 106. NM_025243 (GenBank accession #) represents the main transcript (6 exons, 3775 bp) that encodes a peptide of 496 amino acids (Thiamine transporter-2, THTR-2). The remaining 4 variants were identified from computational annotation and include XM_005246871 (3836 bp, 6 exons, 546 aa), XM_005246874 (3288 bp, 7 exons, 492 aa), XM_006712779 (3210 bp, 6 exons, 501 aa) and XM_005246875 (1257 bp, 4 exons, 383 aa). The stimulating protein-1 (SP1)/ guanosine cytidine (GC) box has been identified in the thiamineresponsive region of SLC19A3 promoter, and SP1 transcriptional factor was reported for regulating THTR-2 expression in response to extracellular thiamine level (Nabokina et al., 2013) .
Pseudogene
Two SLC19A3-related pseudogenes have been reported, namely LOC100130121 locating at chromosome 7p11, and LOC100420667 locating at chromosome 2q37.
The exon/intron structure of SLC19A3 gene (green) and its transcript variants (blue). The coding sequences and untranslated regions are indicated by filled and empty boxes, respectively.
Protein

Note
The protein product of SLC19A3 gene is often referred as thiamine transporter-2 (THTR-2).
Description
A thiamine transporter protein of 496 amino acid residues, 56 kDa, containing 12 transmembrane domains, and cytosolic N-and C-terminals (Eudy et al., 2000) .
Expression
SLC19A3 expression has been widely detetced in human tissues including brain, heart, gastrointestinal tract, lung, pancreas, muscle, ovary, testis, adrenal gland, with the highest levels observed in placenta, liver and kidney (Eudy et al., 2000) . A more restricted pattern of SLC19A3 expression was found in mouse tissues, including only brain, heart, lung, kidney and small intestine.
Localisation
Plasma membrane. In polarized intestinal epithelial cells, THTR-2 are restrictedly localized at the apical membrane domain (Subramanian et al., 2006a) .
Function
THTR-2 mediates the transmembrane uptake of thiamine (vitamin B1) via a proton anti-port mechanism (Rajgopal et al., 2001 ). This thiamine uptake process was reported to be temperature-, energy-and pH-dependent (Ashokkumar et al., 2006; Subramanian et al., 2007) , and is adaptively regulated by the extracellular thiamine level through transcriptional regulation of the SLC19A3 gene (Nabokina et al., 2013) . In human intestinal epithelial cells, THTR-2 interacts with the human transmembrane 4 super-family 4 (TM4SF4) and influences the intestinal thiamine uptake (Subramanian et al., 2014 
Implicated in
Breast cancer
Note SLC19A3 expression was downregulated in breast cancer tumors as compared to the normal tissues (Ng et al., 2011) . Exogenous expression of SLC19A3 in breast cancer cells resulted in an increased sensitivity to doxorubicin-and radiation-induced apoptosis (Liu et al., 2003) , and modulated the gene expression associated with prostaglandin metabolism (Liu et al., 2004) .
Gastric cancer
Note Hypermethylation of SLC19A3 promoter was detected in gastric cancer cell lines and carcinoma tissues, which led to the epigenetic downregulation of SLC19A3 expression (Liu et al., 2009 ). The methylation status of SLC19A3 promoter was further validated in plasma samples of breast and gastric cancer patients, suggesting it as a potential SLC19A3 (solute carrier family 19 (thiamine transporter), member 3) Kwong A, et al. Atlas Genet Cytogenet Oncol Haematol. 2015; 19(6) blood biomarker for cancer diagnosis (Ng et al., 2011) .
Biotin-responsive basal ganglia disease
Note Biotin-responsive basal ganglia disease (BBGD) is a recessive metabolic disorder caused by the homozygous or compound heterozygous mutations in SLC19A3 (Zeng et al., 2005; Debs et al., 2010) . Functional study of SLC19A3 [p.Gly23Val and p.Thr422Ala] mutants demonstrated that these 2 mutations did not affect THTR-2 protein trafficking to the apical membrane, but resulting in impaired thiamine transport activity (Subramanian et al., 2006b ).
Leigh syndrome
Note
Mutational dysfunction of SLC19A3 has been reported to be associated with Leigh syndrome. A nonsense mutation (c.20C>A; p.Ser7*) has been detected in SLC19A3, and was described as a founder mutation in the Moroccan population (Gerards et al., 2013 ).
Wernicke's-like encephalopathy
Note
Compound mutations in SLC19A3 [p.Lys44Glu and p.Glu320Gln] were reported in patients with Wernicke's-like encephalopathy. From the expression study, p.Lys44Glu mutantion resulted in impaired THTR-2 intracellular transport, whereas the p.Glu320Gln mutant showed normal cell surface localization but a significiantly decreased thiamine uptake activity (Kono et al., 2009 ).
Apoptosis
Note THTR2-transfected breast cancer cells were found an increase in sensitivity to chemotherapy agent doxorubicin and ionizing radiation, and an increase in apoptosis involving the caspase-3-dependent pathway (Liu et al., 2003) .
Diabetic nephropathy
Note SLC19A3 expression was demonstrated to be downregulated in kidney proximal tubular epithelium under high glucose concentration, which led to the impaired renal re-uptake of thiamine, and producing thiamine insufficiency. This implies a novel mechanism of renal thiamine mishandling linked to the development of diabetic nephropathy (Larkin et al., 2012) .
Biotin deficiency
Note SLC19A3 expression was found to be strikingly repressed in human leukocytes upon marginal biotin deficiency, suggesting it as a potential indicator of biotin status (Vlasova et al., 2005) .
